TOPIGEN

April 10, 2007 08:00 ET

TOPIGEN Expands Executive Team With Senior Business Development and Pharmaceutical Development Appointments

MONTREAL--(CCNMatthews - April 10, 2007) - TOPIGEN Pharmaceuticals Inc., a development-stage biopharmaceutical company specializing in developing treatments for respiratory diseases, today announced it has expanded its management team with the appointments of company officers Lisa Nolan, Ph.D., and Mark Parry-Billings, Ph.D., to lead TOPIGEN's business development initiatives and pharmaceutical development activities, respectively.

Paul K. Wotton, Ph.D., President and Chief Executive Officer of TOPIGEN, commented on the appointments, "This is a key growth period in TOPIGEN's history. With two lead programs entering late-stage development and opportunities on the horizon to broaden the application of our technology, it is important that we have the right people to take TOPIGEN to the next level of performance. Dr. Nolan's diversified industry knowledge will be key to help us to form optimal alliances. Her extensive licensing experience and proven track record at conceiving and executing transactions will help us to garner the most value by forming advantageous partnerships for our product candidates."

Dr. Wotton continued, "Dr. Parry-Billings has extensive experience in the biopharmaceutical industry managing clinical programs in respiratory diseases and will oversee our pharmaceutical and clinical development programs. Mark also has significant management expertise in the area of device development which is a critical component of our respiratory products. His guidance in trial design and management will be crucial as our lead candidates, TPI ASM8 and TPI 1020, complete Phase II development and enter into Phase III testing."

Dr. Lisa Nolan has over 20 years of experience in the pharmaceutical industry across the areas of clinical research, marketing, business development and strategic planning. She was previously at SkyePharma where she served as Vice President, Business Development, and was responsible for a range of partnering deals, which included the licensing of respiratory technologies and products. Prior to that, Dr. Nolan was Vice President, Business Development, at West Pharmaceutical Services, following clinical research and marketing roles that she held at Elan Corporation and AstraZeneca Pharmaceuticals. Dr. Nolan holds a M.Sc. in Pharmacy and a Ph.D. in Clinical Pharmacology from Trinity College, Dublin.

Dr. Mark Parry-Billings' broad biopharmaceutical industry experience spans the areas of clinical research and development and trial design and management. He was previously Director of Research and Development at pSiMedica Ltd. (a subsidiary of pSivida), a global company developing targeted and controlled release products across a range of therapeutic areas. At pSiMedica Dr. Parry-Billings was responsible for the development of the company's core research programs and oversaw all clinical phases of development. Prior to this, he held research and development positions at Innovata Biomed Ltd. and Schering Healthcare Ltd. Dr. Parry-Billings has a Ph.D. in Biochemistry from the University of Oxford.

About TOPIGEN

TOPIGEN is a privately held, clinical-stage biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory diseases such as asthma, COPD and allergic rhinitis. TOPIGEN's pipeline includes small molecule and RNA-targeting therapeutics. The Company has two lead product candidates, inhaled TPI ASM8 for the treatment of asthma and inhaled TPI 1020 for the treatment of Chronic Obstructive Pulmonary Disease (COPD), both currently undergoing Phase II trials. By topically targeting multiple affected airway receptors, the Company expects to improve outcomes for many patients with respiratory diseases. This specific approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions. Current venture investors include CDP Capital - Technology Ventures, Desjardins Venture Capital, T2C2 / BIO, Fonds de solidarite FTQ, BDC Venture Capital and Multiple Capital Inc. For more detailed information on TOPIGEN visit www.topigen.com.

Contact Information